Edition:
United States

Evolva Holding SA (EVE.S)

EVE.S on Swiss Exchange

0.59CHF
30 Sep 2016
Change (% chg)

CHF0.01 (+1.72%)
Prev Close
CHF0.58
Open
CHF0.58
Day's High
CHF0.59
Day's Low
CHF0.57
Volume
530,160
Avg. Vol
1,135,951
52-wk High
CHF1.33
52-wk Low
CHF0.53

EVE.S

Chart for EVE.S

About

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company’s nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The... (more)

Overall

Beta: 1.92
Market Cap(Mil.): CHF231.25
Shares Outstanding(Mil.): 398.70
Dividend: --
Yield (%): --

Financials

  EVE.S Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -0.09 -- --
ROI: -15.12 -0.29 13.93
ROE: -17.02 -2.99 14.84

BRIEF-Evolva CFO Jakob Dynnes Hansen will leave the company

* Announces that its chief financial officer, Jakob Dynnes Hansen, will leave the company for personal reasons

Sep 20 2016

BRIEF-Evolva Holding H1 2016 revenues at CHF 3.7 million

* H1 2016 revenues of 3.7 million Swiss francs (H1 2015: 8.3 million Swiss francs, of which 4 million Swiss francs econwas non-recurring)

Aug 18 2016

BRIEF-Evolva Holding enters into agreement with private US biotech venture

* Entered into an agreement with private us biotech venture to develop new production routes for existing active pharmaceutical ingredients

Aug 17 2016

BRIEF-Evolva Holding collaborates with US Navy

* Collaboration with US Navy to focus on resveratrol-based composites

Aug 10 2016

BRIEF-Evolva Holding establishes sales office in Singapore

* Establishes sales office in Singapore Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 04 2016

BRIEF-Evolva Holding announces teaming up with Cornelius Group

* Cooperation for marketing of resveratrol in certain European markets Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 28 2016

BRIEF-Evolva Holding: Evolva's nootkatone enters NIH-sponsored studies

* Evolva's nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus

Jul 25 2016

BRIEF-Evolva Holding: resveratrol part of novel combination therapy to be tested

* Resveratrol part of novel combination therapy to be tested in a clinical trial for women with polycystic ovary syndrome Source text: http://bit.ly/29Wcebp Further company coverage: (Gdynia Newsroom)

Jul 13 2016

BRIEF-Evolva: Cargill EverSweet gets No Objection Letter from FDA

* Said on Wednesday partner Cargill issued a press release announcing U.S. FDA issued GRAS No Objection Letter for EverSweet next-generation sweetener

Jun 02 2016

BRIEF-Evolva Holding granted patent number 2742142

* Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Edison Investment Research
$10.00
Provider : Sadif Analytics Prime
$25.00
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.